Replimune REPL
NASDAQ REPL
$15.02 -0.27 (-1.77%)
As of: Sep 4, 2026 · 2:19 PM EDT

Replimune (REPL) EV to CFO (2018 - 2026)

Analysis

Replimune (REPL) EV to CFO (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.92 Bn 131.07 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn
3 Argenx Se 63.55 Bn 58.37 Bn 1.37 Bn
4 Moderna 58.26 Bn 53.13 Bn 52.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn -
6 BeOne Medicines 39.98 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.32 Bn 32.01 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.59 Bn -
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn
10 Replimune 1.45 Bn 1.45 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.70
Mar 31, 2026 -6.48
Dec 31, 2025 -7.65
Sep 30, 2025 -0.06
Jun 30, 2025 -4.15
Mar 31, 2025 -4.98
Dec 31, 2024 -7.81
Sep 30, 2024 -8.22
Jun 30, 2024 -2.96
Mar 31, 2024 -1.76
Dec 31, 2023 -1.09
Sep 30, 2023 -11.79
Jun 30, 2023 -17.09
Mar 31, 2023 -12.73
Dec 31, 2022 -32.32
Sep 30, 2022 -14.67
Jun 30, 2022 -13.95
Mar 31, 2022 -18.09
Dec 31, 2021 -46.82
Sep 30, 2021 -41.51